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Abstract
Background.Patients with low-risk MDS remain dependent on regular transfusions,
acquiring a secondary, post-transfusion excess of iron, which accordingly is an indication for
the appointment of chelation therapy (CT). All over the world this problem continues to be
studied, confirmation that this article cites about 40 sources of literature review.
Methods.Three online medical databases were searched to identify studies reporting the
data on the complex methods of treatment for the correction of iron deficiency condition in
patients with low risk myelodysplastic syndrome. The primary outcome was to learn the
worldwide tendency on this matter and to compare the results of different authors.
Results.Several primary and secondary studies have been published that demonstrate
improved survival of low-risk MDS patients who received chemotherapy. Overall, we
identified 842 items as a result of search. Then we found 156 studies as similar among the
databases that were deleted afterwards. Then, remaining 686 records were screened excluding
512 findings owing to different reasons. Further, the titles of 174 studies were read, 51
articles found as potentially eligible, which obtained in full text. All full text articles were
learnt by the authors of the review. Finally, we included 26 studies to our review.
Conclusion.Chelator therapy is a component of the treatment for low-risk MDS patients
with post-transfusion overload with iron. Its appointment as part of a complex-pathogenetical
therapy should not be formal. The description of iron chelators can reduce transfusion
dependence and increase survival in patients with MDS.
Key words: myelodysplastic syndrome (MDS), acute leukemia, low-risk MDS patients,
anemia, ferritin, erythropoiesis-stimulating drugs, chelator therapy, exjade.
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BACKGROUND
Myelodysplastic syndrome (MDS) is a
group of heterogeneous clonal diseases
characterized by the presence of cytopenia
in peripheral blood (PB), bone marrow
(BM) dysplasia and the risk of
transformation into acute leukemia (AL).
MDS is one of the most severe issues in
hematology today. MDS is more specific
pathology for the older age group. 80% of
cases with MDS occur in people over 60.
Childhood MDS is extremely rare. It is
known that the choice of therapeutic tactics
is largely determined by the patient's age,
somatic condition, risk level by IPSS and
WPSS scale, as well as the availability of a
suitable donor.
The choice of treatment for patients with
MDS is a rather complicated process, and,
first of all, this is characteristic for patients
from the low-risk group. An excess of blast
cells in the bone marrow, especially in
combination with an unfavorable variant of
the karyotype, involves treatment aimed at
preventing further progression of the disease
and/or preparing for transplantation of
allogeneic hematopoietic stem cells.
Those.the hematologist, based mainly on
data on age, somatic status and comorbidity,
selects one of three possible options. These
are protocols for the treatment of acute
myeloid leukemia, hypomethylating drugs in
monotherapy mode or in combination with
other drugs and restraint therapy, which
presupposes the appointment of
predominantly cytostatic tablets.
The task of treating low-risk MDS
patients is the correction of cytopenia and,
above all, anemia (Abrashkina, 2008; and
Klimkovich, 2005). For this category of
patients, the problem is not so much in the
choice of erythropoiesis-stimulating,
immunosuppressive, immunomodulating or
hypomethylating drugs. The analysis of
predictors associated with efficacy allows
correct selection of patients, to reduce the
frequency of transfusion of donor red blood
cells or even completely reject them. The
problem is that not all patients manage to
achieve the answer. Moreover, in most cases
the answer is transient in nature. Thus, if a
patient with low-risk MDS is not a candidate
for transplantation, then he remains
dependent on regular transfusions with
different intensity, as a result, acquires a
secondary, post-transfusion, excess of iron
and, accordingly, there are indications for
the appointment of chelator therapy (CT)
(Rat, 2013).
The effectiveness of iron chelators is
assessed by the level of serum ferritin and
the iron content in the liver and
myocardium, determined by magnetic
resonance imaging. However, taking into
account the negative effect of excess iron on
vital internal organs mediated by damage to
cell structures by products of free radical
oxidation, it is not so much the reduction of
ferritin indices (Suleymanova, 2017;
Greenberg et al, 1997; and Bennett, 2008),
but the problem of a possible reduction in
mortality that is not associated with the
progression of MDS and improving overall
survival (OS) (Kokhno, 2009; Malcovati et
al, 2015; Steensma& Bennett, 2006;
Mitchell et al, 2013). Considering the fact
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that the damaging effect of excess iron on
bone marrow hematopoiesis is not ruled out,
it is possible that the appointment of
chemotherapy can also improve blood
counts. This position is of fundamental
importance, since chronic anemia, as you
know, is an independent factor in the
deterioration of the survival of patients with
MDS (Mitchell et al, 2013).
It is known that the maintenance of iron
homeostasis is ensured by a balance
between the absorption and recycling of a
trace element in the body in the absence of
mechanisms to remove its excess. In this
case, the intake of iron from the intestine
into the blood, carried out with the
participation of ferropoietin, is controlled by
hepsidin (Gattermann et al, 2012; List et al,
2012). A genetically mediated decrease in
the expression and, accordingly, hepcidin
production, observed in particular in patients
with congenital hemochromatosis, is
accompanied by an increase in the level of
serum iron. Reduced hepcidin expression
may also be a consequence of ineffective
erythropoiesis, as, for example, in patients
with thalassemia who do not need
transfusions (Greenberg et al, 2010).
Another reason for the excess iron is
transfusion of donor red blood cells with
accumulation of iron mainly in the cells of
the reticuloendothelial system (Remacha et
al, 2010). Transfusion of 4-5 doses of donor
red blood cells adds approximately 1 gram
of iron to the 4 grams contained in the body.
Under these conditions, the depletion of the
binding ability of ferritin is accompanied by
the appearance of iron unbound with ferritin,
including its aggressive form - the labile
iron of plasma. The accumulation of excess
iron, the formation of labile iron in plasma
and products of free radical oxidation results
in damage to the cells of the myocardium,
liver, pancreas and a number of other organs
with impaired functional activity, which
may ultimately lead to death of the patient
(Rose et al, 2010). It is possible that an
excess of iron may be associated with the
risk of transformation into acute myeloid
leukemia (AML) (Malcovati et al, 2007).
The actuality of studying iron excess
and treatment in patients with low-risk MDS
is not so much the decrease in ferritin, as the
problem of a possible reduction in mortality,
not associated with the progression of MDS,
and improve the overall survival of this
contingent. In Uzbekistan, such studies were
conducted only in patients with thalassemia.
In this connection, it became necessary to
study this problem in patients with MDS.
PURPOSE OF THE STUDY
To study the recent data in the literature
related to the iron excess and treatment in
patients with low-risk MDS and the problem
of a possible reduction in mortality
associated with the progression of MDS. To
analyze improvementin the overall survival
of this contingent.
METHODS
PROTOCOL AND REGISTRATION
The literature review was conducted
following the guidelines set by the Preferred
Reporting Items for Systematic Reviews and
3
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Meta-Analysis (PRISMA) (Moher et al,
2009).
ELIGIBILITY AND EXCLUSION
CRITERIA
Both primary and secondary studies
were included for this review. We did not
apply any restrictions regarding the period
of the publication for studies. Only English
papers were included. The review covered
both prospective as well as retrospective
data analyses. We did not usedfilters for the
country of publication.
SEARCH STRATEGY
Three medical electronic databases
(MEDLINE, EMBASE and Cochrane) were
searched to find the studies reporting the
complex pathogenetic therapeutic tactics for
the correction of iron deficiency condition in
patients with low risk myelodysplastic
syndrome. In the search strategy techniques
on the web sites mentioned above, we used
the following key words:
myelodysplastic syndrome (MDS), acute
leukemia, low-risk MDS patients, anemia,
ferritin, erythropoiesis-stimulating drugs,
chelator therapy, exjade.
STUDY SELECTION
Titles and abstracts of the articles
reviewed by the authors of the study
applying the search methods outlined above
in order to identify the studies that match the
inclusion criteria. Found items were
searched and compared for duplicate
articles, similar studies were deleted.
Eligible studies were checked to find any
more interesting sources for our review.
When we found any interesting paper that
suitable for our criteria of eligibility, full
texts the study were obtained and read till
the end. Any disagreements between
reviewers, resolved by discussion.
RESULTS
STUDY SELECTION.
Overall, 842 items found as a result of
search through databases mentioned above.
Next, we identified 156 identical studies that
were deleted afterwards. Then, remaining
686 records were screened excluding 512
findings owing to different reasons. Further,
the titles of 174 studies were read, 51
articles found as potentially eligible, which
obtained in full text. All full text articles
were learnt by the authors of the review.
Finally, we included 26 studies to our
review. Owing to the different style,
methods and outcomes of the studies
(heterogeneity), we did not perform meta-
analysis.
STUDY CHARACTERISTICS
Today, several papers have been
published that demonstrate improved
survival of low-risk MDS patients who
received chemotherapy. R. Lyons et al.
(2017) reported the results of a 5-year
prospective, non-intervention study that
included 599 low-risk MDS patients over
the age of 18 from 118 US centers. The
diagnosis was established according to the
classification of WHO or FAB, a variant of
the forecast on the IPSS scale. Post-
4
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transfusion iron overload was verified if 20
or more doses of donated red blood cells
were transfused or transfusions continued at
a frequency of ≥6 doses every 12 weeks,
and/or the level of serum ferritin was more
than 1000 ng/ml. The period from the
diagnosis of MDS to inclusion in the study
ranged from 0 to 429.9 months. Vascular
diseases were detected in 54.4% of patients:
arterial hypertension in 50.8% and coronary
heart disease in 25.2%. Diabetes mellitus
and thyroid disease occurred in 24.5% and
21.0% of patients, respectively. Patients
were divided into three groups: without
chemotherapy, chemotherapy and
chemotherapy for a duration of ≥6 months.
The authors found that the appointment of
iron chelators and, above all, long-term
chemotherapy was accompanied by a
significant improvement in survival: 86.3
and 98.7 months, respectively, compared to
47.8 months in the group of patients without
chemotherapy; p <0.0001. One reason is the
significantly higher frequency of deaths
among patients who were not prescribed
chelators: 73.3% versus 62.2% in the CT
group and 59.6% in the CT group for ≥6
months. At the same time, improvement
without progressive survival was
demonstrated. The median time from
diagnosis of MDS to transformation into
AML in the groups was 46.7, 86.3 and 97.8
months, respectively; p <0.0001.
H. Leitch et al. (2017) analyzed data
from 239 MDS patients with low and
intermediate-1 IPSS risk, of which 83
received (Deferazirox, Deferoxamine, or
both drugs sequentially) and 156 did not
receive chemotherapy. In the CT group there
were more young patients and MDS patients
with ring sideroblasts, with a later
development of transfusion dependence and
higher serum ferritin levels. Before or
during chemotherapy, patients received one
of the treatment options commonly used to
treat MDS. The duration of chemotherapy
was from 1.2 to 123.5 months, the median
was 12.4 months. As in the previous work, a
significant improvement in the survival of
patients with the appointment of iron
chelators was found: 5.2 years versus 2.1
years without chemotherapy; p <0.0001.
Given the heterogeneous composition of
patients, the authors evaluated the OM in
groups with comparable clinical and
hematological parameters (age, IPSS-R
variant, transfusion frequency per month,
duration of the period from diagnosis of
MDS to the start of transfusions) and again
revealed significantly worse survival of
patients who did not receive chemotherapy.
At the same time, there were no differences
in the causes of death and without leukemic
survival in comparable groups.
The results of 8 observational studies
published over the period 2008–2014 were
used by A. Mainous et al. (2014) for meta-
analysis. And again, a significant
improvement in the survival of low-risk
MDS patients who received chemotherapy
was demonstrated. The difference in median
OM was 61.2 months, i.e. the appointment
of iron chelators increased survival by 5
years. Since interim data were presented in 3
publications, in 2017 I. Abraham et al.
(2017) presented the results of a new meta-
5
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analysis of the results of 7 observational
studies due to an increase in the observation
time (Kohgo et al, 2008). The result was a
repeat of the conclusion about the direct
dependence of OM of low-risk MDS
patients on the appointment of iron
chelators. Moreover, the difference in
median survival has already reached 74
months, i.e. with the appointment of
chemotherapy, an increase in life
expectancy of 6.2 years is possible.
The mechanisms responsible for
improving the survival of low-risk MDS
patients with the appointment of chelators
are not known. The most attractive
explanation seems to be a decrease in iron
reserves. However, a short monitoring of
serum ferritin and liver iron levels is
insufficient to substantiate this assumption
(Greenberg et al, 2008; Bennett, 2008; and
Gattermann, 2018). Moreover, individual
researchers failed to demonstrate a
significant decrease in ferritin levels even
with prolonged chemotherapy, which casts
doubt on the feasibility of using this
indicator as a marker for assessing the
effectiveness of iron chelators(Kohgo et al,
2008). As possible mechanisms for
improving OM, a decrease in the need for
transfusions of donor red blood cells and a
decrease in the risk of progression in AML
are also considered (Andrews, 2012; Lyons
et al, 2017). But the biological effect of
chelators in the form of a decrease in the
level of iron not associated with ferritin,
labile iron of plasma and products of free
radical oxidation, which helps prevent
damage to vital organs, seems more likely to
occur (Gattermann, 2018; Leitch et al,
2017). An indirect confirmation may be a
decrease in the risk of death with prolonged
use of Deferasirox in an adequate dose
(Andrews, 2012; Mainous et al, 2014; and
Abraham et al, 2017). Zeidan et al. (2015)
found that each additional week of chelator
administration is associated with a reduced
risk of death, especially in the case of
chronic chemotherapy for more than 53
weeks (HR: 0.395; 95% CI: 0.197–0.792; p
= 0.009).
The appointment of iron chelators is
attractive to clinicians not only for the
ability to improve OM. No less important is
the chance to reduce the dependence of
MDS patients on transfusions. On this issue
in the literature one can find a description of
both individual observations and an analysis
of a significant number of cases. The largest
number of MDS patients in the case
histories that were analyzed for the
frequency of achievement of the
hematological response (HR) was included
in the EPIC study - prospective, 1-year,
multicenter, open, stage III to study the
effectiveness of Deferasirox in patients with
excess iron (Lyons et al, 2017). Inclusion
criteria were post-transfusion iron overload,
defined as a ferritin level of ≥1000 ng/ml or
transfusion of more than 20 doses of donor
red blood cells (if the ferritin level was
<1000 ng / ml), or iron concentration in the
liver >2 mg Fe/g dry weight (method MRI
T2 ⃰), as well as the projected life expectancy
of at least 1 year and the absence of another
type of specific therapy. Patients who took
at least one dose of Deferasirox were
6
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selected for post-hoc analysis. Of the 341
MDS patients included in the study,
erythrocyte, platelet, and neutrophil
responses were evaluated in 247, 100, and
50 patients, respectively. The erythrocyte
response was recorded in 21.5% of patients
with a median time to response of 109 days.
At the same time, in 11.3% of patients there
was only a decrease in dependence on
transfusions, in 8.9% only an increase in
hemoglobin concentration, and in 1.2%,
both responses were simultaneous. Platelet
response occurred in 13.0% of patients with
a median time to response of 169 days. A
neutrophilic response was observed in
22.0% of patients with a median time to
response of 226 days. The response was
accompanied by a decrease in ferritin levels.
A decrease in ferritin was also revealed
by other authors (Gattermann et al, 2012),
which suggests that the response is
dependent on a decrease in iron stores. For a
more correct identification of the possible
reasons for improving blood counts and
reducing the need for transfusions with the
appointment of Deferasirox M. Breccia et al.
(2015) analyzed 9 publications describing
individual cases with HR, 4 with the results
of clinical trials and 3 with indicators from
real clinical practice. Aggregate analysis
allowed the authors to admit the role of the
following mechanisms. The direct effect of
chelators on the pathological clone and cells
of the hematopoietic microenvironment.
Stimulation of mechanisms for removing
iron from storage sites with its subsequent
utilization by hematopoietic tissue.
Decreased plasma labile iron and oxygen
free radicals.Suppression of the function of
the transcription factor NF-kb.Suppression
of the intracellular signaling pathway m-
TOR. It should be assumed that the
hematological response is the result of the
joint or sequential functioning of several of
the above mechanisms initiated by the use of
iron chelators. This, in part, can explain the
absence of HR in other MDS patients.
DISCUSSIONS
The review of the recent literature on
the topic of complex treatment of iron
deficiency condition in patients with low
risk myelodysplastic syndrome showed that
there are some shortcomings in studies
evaluating the effectiveness of chelators.
Moreover, this includes the lack of
randomization and the possible selection of
patients with a more favorable prognosis in
the CT group, yet, the available data allow
us to expect improved survival and reduced
transfusion dependence when prescribing
iron chelators.
For this, as follows from the already
mentioned studies (Kohgo et al, 2008; and
Mainous et al, 2014) and the study of M.
Delforge et al. (2014), compliance with 2
fundamental conditions is necessary: dose
adequacy and duration of therapy. Given the
possible toxic complications when taking
Deferasirox, the next important condition is
clinical and laboratory monitoring with
timely dose adjustment. The most common
complications of prescribing Deferasirox
(exjad) include gastrointestinal upsets and
an increase in creatinine levels (Zeidan et al,
2015), which are reversible in compliance
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with the recommendations prescribed in the
instructions, i.e. timely dose reduction,
interruption or withdrawal. Taking exjade
half an hour before dinner and gradually
increasing the dosage under the control of
serum ferritin levels can prevent the
development of adverse events (Rose et al,
2010). Exjade, which is available in the
form of coated tablets, the patient takes 30
mg / kg per day (Rose et al, 2010; Breccia et
al, 2015; Delforge et al, 2014; Cermak et al,
201; Nolte et al, 2015).
CONCLUSION
Chelator therapy is a component of the
algorithm of treatmentfor low-risk MDS
patients with post-transfusion overload with
iron. Its appointment as part of a complex-
pathogenetical therapy should not be formal
due to only the identification of criteria for
excess iron in the body. The description of
iron chelators can reduce transfusion
dependence and increase survival in patients
with MDS. The conditions for a complex-
pathogeneticallysubstantiated manifestation
of the clinical effectiveness of chelator
therapy are careful selection of candidates,
timely dose adjustment and long-term use of
chelators. In Uzbekistan, chelator therapy
with the use of exjade in patients with
thalassemia is successfully used, only the
complex pathogenetically substantiated
prescription of therapeutic drugs is provided
at the expense of state funds.
STUDY LIMITATIONS
The review did not include the quality
assessment and risk of bias within included
studies. This might affect the general
outcomes as well as conclusion of this
review. Thus, further literature review and
meta-analyses on this topic can be
conducted with the quality assessment.
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